TrialSignal
Clinical trial intelligence report
A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03426605-Jul 28, 2026
NCT ID
NCT03426605
Status
COMPLETED
Phase
Phase 1
Sponsor
OrphAI Therapeutics
Executive brief
Investment-Ready Snapshot
LAM-003 is currently in Phase 1 clinical trials for the treatment of Acute Myeloid Leukemia (AML). The market for AML therapies is competitive, with several established treatments and emerging therapies. The successful completion of this trial could position OrphAI Therapeutics favorably in a market that is increasingly focused on novel agents for relapsed or refractory AML. Given the limited treatment options for patients with relapsed AML, LAM-003 may address a significant unmet need, potentially enhancing its commercial viability. Diligence should focus on the safety profile, efficacy outcomes, and the competitive landscape, particularly regarding other investigational agents in similar stages of development.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03426605
Indication
Oncology
Modality
small molecule
Target
Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of LAM-003.
Intervention
Open Label LAM-003
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.